Jianchun Guo

Dr. Jianchun Guo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HCHaitao Chen
Haitao Chen
JLJun Luo
Jun Luo
JGJianchun Guo
Jianchun Guo
Background: Colon cancer is a common and highly malignant cancer. Its morbidity is rapidly increasing, and its prognosis is poor. Currently, immunotherapy is a rapidly developing therapeutic modality of colon cancer. This study aimed to construct a prognostic risk model based on immune genes for the early diagnosis and accurate prognostic prediction of colon cancer. Methods: Transcriptomic data and clinical data were downloaded from The Cancer Genome Atlas database. Immune genes were obtained from the ImmPort database. Differentially expressed (DE) immune genes between 473 colon cancer and 41 adjacent normal tissues were identified. The entire cohort was randomly divided into the training and testing cohort. The training cohort was used to construct the prognostic model. The testing and entire cohorts were used to validate the model. The clinical utility of the model and its correlation with immune cell infiltration were analyzed. Results: A total of 333 DE immune genes (176 up-regulated and 157 down-regulated) were detected. We developed and validated a five-immune gene model of colon cancer, including LBP, TFR2, UCN, UTS2, and MC1R. This model was approved to be an independent prognostic variable, which was more accurate than age and the pathological stage for predicting overall survival at five years. Besides, as the risk score increased, the content of CD8+ T cells in colon cancer was decreased. Conclusions: We developed and validated a five-immune gene model of colon cancer, including LBP, TFR2, UCN, UTS2, and MC1R. This model could be used as an instrumental variable in the prognosis prediction of colon cancer.

4 December 2020 in Medical Science Monitor
Verified
Journal Article
Closed access
HCHaitao Chen
Haitao Chen
JLJun Luo
Jun Luo
JGJianchun Guo
Jianchun Guo
Background: We constructed a predictive risk model of esophageal carcinoma (EC) for prognostic prediction. Material/Methods: Immune genes and the expression data were downloaded from the ImmPort database and The Cancer Genome Atlas database. Univariate analysis, Lasso regression, and multivariate analysis were applied to screen the ultimately included prognostic immune genes for the model based on the training cohort. Survival analysis and receiver operating characteristic (ROC) curve were applied to evaluate the model. The model was further validated in the testing and entire cohorts, and the clinical utility of the model and its ability to assess the subtypes of EC were evaluated in the entire cohort. Results: We detected 297 differentially expressed immune genes, including 241 upregulated genes and 56 downregulated genes in EC patients. Based on these genes, we developed a 7-immune gene model of EC, including HSPA6, S100A12, NOS2, DKK1, OSM, AR, and OXTR. The area under the curve (AUC) of the model at 1 year was 0.825. Similarly, the AUC values for the validating cohorts were 0.813 and 0.816, respectively. Pathological stage and risk score of the model were independent prognostic factors. This model was effective for both subtypes of EC. Conclusions: We constructed a 7-gene model consisting of HSPA6, S100A12, NOS2, DKK1, OSM, AR, and OXTR. This risk model could be used for prognostic prediction of EC.

16 March 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HCHaitao Chen
Haitao Chen
YLYueying Li
Yueying Li
SXShu-Yuan Xiao
Shu-Yuan Xiao
JGJianchun Guo
Jianchun Guo
Background: Hepatocellular carcinoma (HCC) is a common malignant tumor with a poor prognosis. We aimed to identify a new prognostic model of HCC based on differentially expressed (DE) immune genes. Methods: The DE immune genes were identified based on an analysis of 374 cases of HCC and 50 adjacent non-tumor specimens from the Cancer Genome Atlas (TCGA) database. Univariate Cox analysis, Lasso regression, and multivariate Cox analysis were used to construct the model based on the training group. Survival analysis and the receiver operating characteristic (ROC) curves were used to evaluate model performance. The testing group and the entire group were subsequently used for validation of the model. Results: A five-immune gene model consisted of HSPA4, ISG20L2, NDRG1, EGF, and IL17D was identified. Based on the model, the overall survival was significantly different between the high-risk and low-risk groups (P = 7.953e-06). The AUCs for the model at 1- and 3-year were 0.849 and 0.74, respectively. The reliability of the model was confirmed using the validation groups. The risk score was identified as an independent prognostic parameter and closely related to the content of immune cells from human HCC specimens. Conclusion: We identified a five-immune gene model that can be used as an independent prognostic marker for HCC.

25 April 2020 in Pathology - Research and Practice
Verified
Journal Article
Closed access
STSufang Tian
Sufang Tian
JGJianchun Guo
Jianchun Guo
XTXianbin Tang
Xianbin Tang
YLYufei Liu
Yufei Liu
Honglei ChenHonglei Chen
Honglei Chen
SXShu-Yuan Xiao
Shu-Yuan Xiao

22 September 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HCHaitao Chen
Haitao Chen
JLJun Luo
Jun Luo
JGJianchun Guo
Jianchun Guo
Background: Colon cancer is a common malignant tumor with a poor prognosis. Abnormal alternative splicing (AS) events played a part in the occurrence and metastasis of the tumor. We aimed to develop a survival-associated AS signature in colon cancer. Methods: The Percent Spliced In values of AS events were available in The Cancer Genome Atlas (TCGA) SpliceSeq database. Univariate Cox analysis was carried out to detect the prognosis-related AS events. We created a predictive model on account of the survival-associated AS events, which was further validated with a training-testing group design. Kaplan-Meier analysis was applied to assess patient survival. The area under curve (AUC) of receiver operating characteristic (ROC) was performed to evaluate the predictive values of this model. Meanwhile, the clinical relevance of the signature and its regulatory relationship with splicing factors (SFs) were also evaluated. Results: In total, 2132 survival-related AS events were identified from colon cancer samples. We developed an eleven-AS signature, in which the 5-year AUC value was 0.911. Meanwhile, the AUC values at five years were 0.782 and 0.855 in the testing and entire cohort, respectively. Multivariate Cox regression displayed that the T category and the risk score of the signature were independent risk factors of colon cancer survival. Also, we constructed an SFs-AS network based on 11 SFs and 48 AS events. Conclusions: We identified an eleven-AS signature of colon cancer. This signature could be treated as an independent prognostic factor.

15 July 2020 in Research Square
Verified
Preprint
Open access
PDF file
HCHaitao Chen
Haitao Chen
JGJianchun Guo
Jianchun Guo
Background: Hepatocellular carcinoma (HCC) is a common cancer with a poor prognosis. We purposed to identify a prognostic risk model of HCC according to the differentially expressed (DE) immune genes.Methods: The DE immune genes were identified based on 374 HCC and 50 adjacent normal samples from the Cancer Genome Atlas database. Univariate Cox analysis, Lasso regression, and multivariate Cox analysis were used to determine the immune genes used to construct the model based on the training group. The testing group and the entire group were applied for the validation of the model.Results: A five-immune gene model comprising HSPA4, ISG20L2, NDRG1, EGF, and IL17D was identified. Based on the model, overall survival was significantly different between the high-risk and low-risk groups (P = 7.953e-06). The AUC for the model at 1- and 3-year was 0.849 and 0.74, respectively. The validating groups confirmed the reliability of the model. The risk score was identified as an independent prognostic factor and was closely related to the content of immune cells from HCC samples.Conclusion: We identified a five-immune gene model, which could be treated as an independent prognostic factor of HCC.